Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhu-pGelsolin in ICU patients with low gelsolin
NCT00671307Phase 2Completed
- Sponsor
- Critical Biologics Corporation
- Start
- Mar 2008
- Primary completion
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Recombinant human plasma gelsolin in Hypogelsolinemia (4 arms), sponsored by Critical Biologics Corporation. Primary endpoint: Pharmacokinetics of plasma gelsolin at 72 hours. Started Mar 2008; status: completed.
02
Drugs
Recombinant human plasma gelsolin
03
Conditions
Hypogelsolinemia
Beyond the preview
Go deeper on NCT00671307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671307.